Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus

Comparative Study of Incretin System in Three Ethnic Groups With Abnormal Glucose Tolerance

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03659461

Acronym

GLP-1

Enrollment

174

Registered

2018-09-06

Start date

2017-10-01

Completion date

2020-01-31

Last updated

2022-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes, Type 2 Diabetes Mellitus

Brief summary

This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different GLP-levels.

Interventions

DRUGSitagliptin

oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects are newly diagnosed of T2DM according to World Health Organisation criteria) and do not receive any glucose-lowering drugs * Subjects with normal glucose tolerance test according to World Health Organisation criteria which is carried out immediately before inclusion in the study * Subjects who are willing to participate and sign the informed consent form

Exclusion criteria

* Patients with pre-existing T2DM * Patients with family history of diabetes * Patients receiving glucose-lowering medications * Patients with anemia, abnormal serum creatinine level, macroalbuminuria, proliferative retinopathy, impaired liver function

Design outcomes

Primary

Measure	Time frame	Description
change in blood glucose load response to sitagliptin	pre-treatment of sitagliptin and post 12-week treatment of sitagliptin	change from blood glucose response at 12 weeks
change in blood insulin response to sitagliptin	pre-treatment of sitagliptin and post 12-week treatment of sitagliptin	change from blood insulin response at 12 weeks

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026